<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>0121-5469</journal-id>
<journal-title><![CDATA[Revista Colombiana de Psicología]]></journal-title>
<abbrev-journal-title><![CDATA[Rev. colomb. psicol.]]></abbrev-journal-title>
<issn>0121-5469</issn>
<publisher>
<publisher-name><![CDATA[Universidad Nacional de Colombia, Facultad de Ciencias Humanas, Departamento de Psicología]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S0121-54692020000100143</article-id>
<article-id pub-id-type="doi">10.15446/rcp.v29n1.75930</article-id>
<title-group>
<article-title xml:lang="en"><![CDATA[Review: Does Gabapentin Relieve Opioid, Cannabis and Methamphetamine Addictions?]]></article-title>
<article-title xml:lang="es"><![CDATA[Revisión: ¿La Gabapentina Alivia las Adicciones a los Opiáceos, el Cannabis y las Metanfetaminas?]]></article-title>
<article-title xml:lang="pt"><![CDATA[Revisão: A Gabapentina Reduz o Vício em Drogas Opiáceas, em Cannabis e em Metanfetaminas?]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[QUINTERO GARZOLA]]></surname>
<given-names><![CDATA[GABRIEL CONRADO]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Florida State University  ]]></institution>
<addr-line><![CDATA[Panama ]]></addr-line>
<country>Panama</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>06</month>
<year>2020</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>06</month>
<year>2020</year>
</pub-date>
<volume>29</volume>
<numero>1</numero>
<fpage>143</fpage>
<lpage>161</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://www.scielo.org.co/scielo.php?script=sci_arttext&amp;pid=S0121-54692020000100143&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.co/scielo.php?script=sci_abstract&amp;pid=S0121-54692020000100143&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.co/scielo.php?script=sci_pdf&amp;pid=S0121-54692020000100143&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="en"><p><![CDATA[Abstract The study reviews the suitability of using Gabapentin for treating opioid, cannabis and methamphetamine use disorders. This revision consists of 61 biographical references based on a PubMed database search (January of 1983-May of 2018). Gabapentin displayed respectively 50% and 66.7% of success for treating methamphetamine dependence and opioid withdrawal symptoms. Furthermore, a few research studies have reported Gabapentin's efficacy for alleviating cannabis dependence (two studies), and cannabis withdrawal symptoms (one study). Similarly, a single study reported Gabapentin reduction of opioid consumption during the detoxification process. Based on the revision, we can conclude that: (a) Gabapentin is useful for treating opioid withdrawal symptoms, (b) additional studies are necessary for elucidating the effectiveness of Gabapentin for treating methamphetamine dependence, cannabis dependence and its withdrawal symptoms, and (c) more studies are necessary to confirm the efficacy of Gabapentin in reducing opioid consumption during detoxification.]]></p></abstract>
<abstract abstract-type="short" xml:lang="es"><p><![CDATA[Resumen El trabajo revisa 61 referencias bibliográficas, producto de una búsqueda en la base de datos PubMed (enero de 1983 a mayo de 2018), con el fin de determinar si la Gabapentina es adecuada para el tratamiento de trastornos derivados del uso de opiáceos, cannabis y metanfetaminas. El éxito de la Gabapentina para tratar la dependencia a las metanfetaminas y los síntomas de abstinencia de opiáceos fue de 50% y 66.7%, respectivamente. Algunas investigaciones han informado la eficacia de la Gabapentina para aliviar la dependencia al cannabis (dos estudios) y los síntomas de abstinencia del cannabis (un estudio). Un solo estudio reportó que la Gabapentina redujo el consumo de opiáceos, durante el proceso de desintoxicación. La revisión nos permite concluir que (a) la Gabapentina es útil para tratar los síntomas de abstinencia de los opiáceos, (b) se necesitan más estudios para esclarecer la efectividad de la Gabapentina para tratar la dependencia a las metan-fetaminas, al cannabis y los síntomas de abstinencia, y (c) se requieren más estudios para confirmar la eficacia de la Gabapentina para reducir el consumo de opiáceos durante la desintoxicación.]]></p></abstract>
<abstract abstract-type="short" xml:lang="pt"><p><![CDATA[Resumo A partir de uma busca na base de dados PubMed (janeiro de 1983 a maio de 2018), são revisadas 61 referências bibliográficas a fim de determinar se a gabapentina é adequada para tratar transtornos derivados do uso de opiáceos, cannabis e metanfetaminas. O sucesso do uso da gabapentina para tratar a dependência das metanfetaminas e dos sintomas de abstinência de opiáceos foi de 50% e 66,7%, respectivamente. Algumas pesquisas relatam a eficácia da gabapentina para aliviar a dependência de cannabis (dois estudos) e dos sintomas de abstinência de cannabis (um estudo). Somente um estudo relatou que a gabapentina reduzia o consumo de opiáceos durante o processo de desintoxicação. A revisão nos permite concluir que: (a) a gabapentina é útil para tratar os sintomas de abstinência dos opiáceos, (b) é necessário mais estudos para esclarecer a efetividade da gabapentina para tratar a dependência das metanfetaminas, da cannabis e dos sintomas de abstinência e (c) são necessários mais estudos para confirmar a eficácia da gabapentina para reduzir o consumo de opiáceos durante a desintoxicação.]]></p></abstract>
<kwd-group>
<kwd lng="en"><![CDATA[cannabis]]></kwd>
<kwd lng="en"><![CDATA[gabapentin]]></kwd>
<kwd lng="en"><![CDATA[methamphetamine]]></kwd>
<kwd lng="en"><![CDATA[opioids]]></kwd>
<kwd lng="en"><![CDATA[treatment]]></kwd>
<kwd lng="es"><![CDATA[cannabis]]></kwd>
<kwd lng="es"><![CDATA[Gabapentina]]></kwd>
<kwd lng="es"><![CDATA[metanfetaminas]]></kwd>
<kwd lng="es"><![CDATA[opiáceos]]></kwd>
<kwd lng="es"><![CDATA[tratamiento]]></kwd>
<kwd lng="pt"><![CDATA[cannabis]]></kwd>
<kwd lng="pt"><![CDATA[gabapentina]]></kwd>
<kwd lng="pt"><![CDATA[metanfetaminas]]></kwd>
<kwd lng="pt"><![CDATA[opiáceos]]></kwd>
<kwd lng="pt"><![CDATA[tratamento]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Adler]]></surname>
<given-names><![CDATA[C. H]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Treatment of restless legs síndrome with Gabapentin]]></article-title>
<source><![CDATA[Clin Neuropharmacol]]></source>
<year>1997</year>
<volume>20</volume>
<page-range>148-51</page-range></nlm-citation>
</ref>
<ref id="B2">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ahmed]]></surname>
<given-names><![CDATA[S.]]></given-names>
</name>
<name>
<surname><![CDATA[Bachu]]></surname>
<given-names><![CDATA[R.]]></given-names>
</name>
<name>
<surname><![CDATA[Kotapati]]></surname>
<given-names><![CDATA[P.]]></given-names>
</name>
<name>
<surname><![CDATA[Adnan]]></surname>
<given-names><![CDATA[M.]]></given-names>
</name>
<name>
<surname><![CDATA[Ahmed]]></surname>
<given-names><![CDATA[R.]]></given-names>
</name>
<name>
<surname><![CDATA[Farooq]]></surname>
<given-names><![CDATA[U.]]></given-names>
</name>
<name>
<surname><![CDATA[Saeed]]></surname>
<given-names><![CDATA[H.]]></given-names>
</name>
<name>
<surname><![CDATA[Khan]]></surname>
<given-names><![CDATA[A. M.]]></given-names>
</name>
<name>
<surname><![CDATA[Zubair]]></surname>
<given-names><![CDATA[A.]]></given-names>
</name>
<name>
<surname><![CDATA[Qamar]]></surname>
<given-names><![CDATA[I.]]></given-names>
</name>
<name>
<surname><![CDATA[Begum]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Use of Gabapentin in the treatment of substance use and psychiatric disorders: A Systematic Review]]></article-title>
<source><![CDATA[Front Psychiatry]]></source>
<year>2019</year>
<volume>10</volume>
<page-range>228</page-range></nlm-citation>
</ref>
<ref id="B3">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Arumugam]]></surname>
<given-names><![CDATA[S.]]></given-names>
</name>
<name>
<surname><![CDATA[Lau]]></surname>
<given-names><![CDATA[C. S.]]></given-names>
</name>
<name>
<surname><![CDATA[Chamberlain]]></surname>
<given-names><![CDATA[R. S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Use of preoperative Gabapentin significantly reduces postoperative opioid consumption: a meta-analysis]]></article-title>
<source><![CDATA[J Pain Res]]></source>
<year>2016</year>
<volume>9</volume>
<page-range>631-40</page-range></nlm-citation>
</ref>
<ref id="B4">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Balter]]></surname>
<given-names><![CDATA[R. E.]]></given-names>
</name>
<name>
<surname><![CDATA[Cooper]]></surname>
<given-names><![CDATA[Z. D.]]></given-names>
</name>
<name>
<surname><![CDATA[Haney]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Novel pharmacologic approaches to treating cannabis use disorder]]></article-title>
<source><![CDATA[Curr Addict Rep]]></source>
<year>2014</year>
<volume>1</volume>
<page-range>137-43</page-range></nlm-citation>
</ref>
<ref id="B5">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bartoszyk]]></surname>
<given-names><![CDATA[G. D.]]></given-names>
</name>
<name>
<surname><![CDATA[Hamer]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The genetic animal model of reflex epilepsy in the Mongolian gerbil: Differential efficacy of new anticonvulsive drugs and prototype antiepileptics]]></article-title>
<source><![CDATA[Pharmacol Res Commun]]></source>
<year>1987</year>
<volume>19</volume>
<page-range>429-40</page-range></nlm-citation>
</ref>
<ref id="B6">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bauer]]></surname>
<given-names><![CDATA[C. S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[A new look at calcium channel &#945;2&#948; subunits]]></article-title>
<person-group person-group-type="editor">
<name>
<surname><![CDATA[Tran-Van-Minh]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Kadurin]]></surname>
<given-names><![CDATA[I.]]></given-names>
</name>
<name>
<surname><![CDATA[Dolphin]]></surname>
<given-names><![CDATA[A. C]]></given-names>
</name>
</person-group>
<source><![CDATA[Current Opinion in Neurobiology]]></source>
<year>2010</year>
<volume>20</volume>
<page-range>1-9</page-range></nlm-citation>
</ref>
<ref id="B7">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Berlin]]></surname>
<given-names><![CDATA[R. K.]]></given-names>
</name>
<name>
<surname><![CDATA[Butler]]></surname>
<given-names><![CDATA[P. M.]]></given-names>
</name>
<name>
<surname><![CDATA[Perloff]]></surname>
<given-names><![CDATA[M. D]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Gabapentin therapy in psychiatric disorders: A systematic review]]></article-title>
<source><![CDATA[Prim Care Companion cns Disord]]></source>
<year>2015</year>
<volume>17</volume>
</nlm-citation>
</ref>
<ref id="B8">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bockbrader]]></surname>
<given-names><![CDATA[H. N.]]></given-names>
</name>
<name>
<surname><![CDATA[Wesche]]></surname>
<given-names><![CDATA[D.]]></given-names>
</name>
<name>
<surname><![CDATA[Miller]]></surname>
<given-names><![CDATA[R.]]></given-names>
</name>
<name>
<surname><![CDATA[Chapel]]></surname>
<given-names><![CDATA[S.]]></given-names>
</name>
<name>
<surname><![CDATA[Janiczek]]></surname>
<given-names><![CDATA[N.]]></given-names>
</name>
<name>
<surname><![CDATA[Burger]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[A comparison of the pharmacokinetics and pharmacodynamics of Pregabalin and Gabapentin]]></article-title>
<source><![CDATA[Clin Pharmacokinet]]></source>
<year>2010</year>
<volume>49</volume>
<page-range>661-9</page-range></nlm-citation>
</ref>
<ref id="B9">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Brackins]]></surname>
<given-names><![CDATA[T.]]></given-names>
</name>
<name>
<surname><![CDATA[Brahm]]></surname>
<given-names><![CDATA[N. C.]]></given-names>
</name>
<name>
<surname><![CDATA[Kissack]]></surname>
<given-names><![CDATA[J. C]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Treatments for methamphetamine abuse: a literatura review for the clinician]]></article-title>
<source><![CDATA[J Pharm Pract]]></source>
<year>2011</year>
<volume>24</volume>
<page-range>541-50</page-range></nlm-citation>
</ref>
<ref id="B10">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Coderre]]></surname>
<given-names><![CDATA[T. J.]]></given-names>
</name>
<name>
<surname><![CDATA[Kumar]]></surname>
<given-names><![CDATA[N.]]></given-names>
</name>
<name>
<surname><![CDATA[Lefebvre]]></surname>
<given-names><![CDATA[C. D.]]></given-names>
</name>
<name>
<surname><![CDATA[Yu]]></surname>
<given-names><![CDATA[J. S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[A comparison of the glutamate reléase inhibition and anti-allodynic effects of Gabapentin, Lamotrigine, and Riluzole in a model of neuropathic pain]]></article-title>
<source><![CDATA[J Neurochem]]></source>
<year>2007</year>
<volume>100</volume>
<page-range>1289-99</page-range></nlm-citation>
</ref>
<ref id="B11">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Crawford]]></surname>
<given-names><![CDATA[P.]]></given-names>
</name>
<name>
<surname><![CDATA[Ghadiali]]></surname>
<given-names><![CDATA[E.]]></given-names>
</name>
<name>
<surname><![CDATA[Lane]]></surname>
<given-names><![CDATA[R.]]></given-names>
</name>
<name>
<surname><![CDATA[Blumhardt]]></surname>
<given-names><![CDATA[L.]]></given-names>
</name>
<name>
<surname><![CDATA[Chadwick]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Gabapentin as an antiepileptic drug in man]]></article-title>
<source><![CDATA[J Neurol Neurosurg Psychiatry]]></source>
<year>1987</year>
<volume>50</volume>
<page-range>682-6</page-range></nlm-citation>
</ref>
<ref id="B12">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Cunningham]]></surname>
<given-names><![CDATA[M. O.]]></given-names>
</name>
<name>
<surname><![CDATA[Woodhall]]></surname>
<given-names><![CDATA[G. L.]]></given-names>
</name>
<name>
<surname><![CDATA[Thompson]]></surname>
<given-names><![CDATA[S. E.]]></given-names>
</name>
<name>
<surname><![CDATA[Dooley]]></surname>
<given-names><![CDATA[D. J.]]></given-names>
</name>
<name>
<surname><![CDATA[Jones]]></surname>
<given-names><![CDATA[R. S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Dual effects of Gabapentin and Pregabalin on glutamate release at rat entorhinal synapses in vitro]]></article-title>
<source><![CDATA[Eur J Neurosci]]></source>
<year>2004</year>
<volume>20</volume>
<page-range>1566-76</page-range></nlm-citation>
</ref>
<ref id="B13">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Dickenson]]></surname>
<given-names><![CDATA[A. H.]]></given-names>
</name>
<name>
<surname><![CDATA[Ghandehari]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Anti-convulsants and anti-depressants]]></article-title>
<source><![CDATA[Handb Exp Pharmacol]]></source>
<year>2007</year>
<volume>177</volume>
<page-range>145-77</page-range></nlm-citation>
</ref>
<ref id="B14">
<nlm-citation citation-type="book">
<collab>Drug Information Portal</collab>
<source><![CDATA[Search Drug Information Portal. Bethesda]]></source>
<year>2018</year>
<publisher-loc><![CDATA[U.S.A: U.S ]]></publisher-loc>
<publisher-name><![CDATA[National Library of Medicine]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B15">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Eroglu]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Gabapentin receptor a2d-1 is a neuronal thrombospondin receptor responsible for excitatory CNS synaptogenesis]]></article-title>
<person-group person-group-type="editor">
<name>
<surname><![CDATA[Allen]]></surname>
<given-names><![CDATA[N. J]]></given-names>
</name>
<name>
<surname><![CDATA[Susman]]></surname>
<given-names><![CDATA[M. W]]></given-names>
</name>
<name>
<surname><![CDATA[O&#8217;Rourke]]></surname>
<given-names><![CDATA[N. A]]></given-names>
</name>
<name>
<surname><![CDATA[Park]]></surname>
<given-names><![CDATA[C. Y]]></given-names>
</name>
<name>
<surname><![CDATA[Ozkan]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Barres]]></surname>
<given-names><![CDATA[B. A]]></given-names>
</name>
</person-group>
<source><![CDATA[Cell]]></source>
<year>2009</year>
<volume>139</volume>
<page-range>380-92</page-range></nlm-citation>
</ref>
<ref id="B16">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Gorelick]]></surname>
<given-names><![CDATA[D. A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Pharmacological treatment of cannabis-related disorders: a narrative review]]></article-title>
<source><![CDATA[Curr Pharm Des]]></source>
<year>2016</year>
<volume>22</volume>
<page-range>6409-19</page-range></nlm-citation>
</ref>
<ref id="B17">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hah]]></surname>
<given-names><![CDATA[J.]]></given-names>
</name>
<name>
<surname><![CDATA[Mackey]]></surname>
<given-names><![CDATA[S. C.]]></given-names>
</name>
<name>
<surname><![CDATA[Schmidt]]></surname>
<given-names><![CDATA[P.]]></given-names>
</name>
<name>
<surname><![CDATA[McCue]]></surname>
<given-names><![CDATA[R.]]></given-names>
</name>
<name>
<surname><![CDATA[Humphreys]]></surname>
<given-names><![CDATA[K.]]></given-names>
</name>
<name>
<surname><![CDATA[Trafton]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Effect of perioperative Gabapentin on postoperative pain resolution and opioid cessation in a mixed surgical cohort: a randomized clinical trial]]></article-title>
<person-group person-group-type="editor">
<name>
<surname><![CDATA[Carroll]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
</person-group>
<source><![CDATA[jama Surg]]></source>
<year>2018</year>
<volume>153</volume>
<page-range>303-11</page-range></nlm-citation>
</ref>
<ref id="B18">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Heinzerling]]></surname>
<given-names><![CDATA[K. G.]]></given-names>
</name>
<name>
<surname><![CDATA[Shoptaw]]></surname>
<given-names><![CDATA[S.]]></given-names>
</name>
<name>
<surname><![CDATA[Peck]]></surname>
<given-names><![CDATA[J. A.]]></given-names>
</name>
<name>
<surname><![CDATA[Yang]]></surname>
<given-names><![CDATA[X.]]></given-names>
</name>
<name>
<surname><![CDATA[Liu]]></surname>
<given-names><![CDATA[J.]]></given-names>
</name>
<name>
<surname><![CDATA[Roll]]></surname>
<given-names><![CDATA[J.]]></given-names>
</name>
<name>
<surname><![CDATA[Ling]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Randomized, placebocontrolled trial of Baclofen and Gabapentin for the treatment of methamphetamine dependence]]></article-title>
<source><![CDATA[Drug Alcohol Depend]]></source>
<year>2006</year>
<volume>85</volume>
<page-range>177-84</page-range></nlm-citation>
</ref>
<ref id="B19">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hengy]]></surname>
<given-names><![CDATA[H.]]></given-names>
</name>
<name>
<surname><![CDATA[Kolle]]></surname>
<given-names><![CDATA[E. U]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Determination of Gabapentin in plasma and urine by high-performance liquid chromatography and pre-column labelling for ultraviolet detection]]></article-title>
<source><![CDATA[J Chromatogr]]></source>
<year>1985</year>
<volume>341</volume>
<page-range>473-8</page-range></nlm-citation>
</ref>
<ref id="B20">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Howland]]></surname>
<given-names><![CDATA[R. H]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Gabapentin for the treatment of substance use disorders]]></article-title>
<source><![CDATA[J Psychosoc Nurs Ment Health Serv]]></source>
<year>2013</year>
<volume>51</volume>
<page-range>11-4</page-range></nlm-citation>
</ref>
<ref id="B21">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Howland]]></surname>
<given-names><![CDATA[R. H]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Gabapentin for substance use disorders: is it safe and appropriate?]]></article-title>
<source><![CDATA[J Psychosoc Nurs Ment Health Serv]]></source>
<year>2014</year>
<volume>52</volume>
<page-range>13-6</page-range></nlm-citation>
</ref>
<ref id="B22">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Karila]]></surname>
<given-names><![CDATA[L.]]></given-names>
</name>
<name>
<surname><![CDATA[Weinstein]]></surname>
<given-names><![CDATA[A.]]></given-names>
</name>
<name>
<surname><![CDATA[Aubin]]></surname>
<given-names><![CDATA[H. J.]]></given-names>
</name>
<name>
<surname><![CDATA[Benyamina]]></surname>
<given-names><![CDATA[A.]]></given-names>
</name>
<name>
<surname><![CDATA[Reynaud]]></surname>
<given-names><![CDATA[M.]]></given-names>
</name>
<name>
<surname><![CDATA[Batki]]></surname>
<given-names><![CDATA[S. L]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Pharmacological approaches to methamphetamine dependence: a focused review]]></article-title>
<source><![CDATA[Br J Clin Pharmacol]]></source>
<year>2010</year>
<volume>69</volume>
<page-range>578-92</page-range></nlm-citation>
</ref>
<ref id="B23">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kheirabadi]]></surname>
<given-names><![CDATA[G. R.]]></given-names>
</name>
<name>
<surname><![CDATA[Ranjkesh]]></surname>
<given-names><![CDATA[M.]]></given-names>
</name>
<name>
<surname><![CDATA[Maracy]]></surname>
<given-names><![CDATA[M. R.]]></given-names>
</name>
<name>
<surname><![CDATA[Salehi]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Effect of add-on Gabapentin on opioid withdrawal symptoms in opium-dependent patients]]></article-title>
<source><![CDATA[Addiction]]></source>
<year>2008</year>
<volume>103</volume>
<page-range>1495-9</page-range></nlm-citation>
</ref>
<ref id="B24">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kurokawa]]></surname>
<given-names><![CDATA[K.]]></given-names>
</name>
<name>
<surname><![CDATA[Shibasaki]]></surname>
<given-names><![CDATA[M.]]></given-names>
</name>
<name>
<surname><![CDATA[Mizuno]]></surname>
<given-names><![CDATA[K.]]></given-names>
</name>
<name>
<surname><![CDATA[Ohkuma]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Gabapentin blocks methamphetamine-induced sensitization and conditioned place preference via inhibition of alpha(2)/delta-1 subunits of the voltagegated Calcium channels]]></article-title>
<source><![CDATA[Neuroscience]]></source>
<year>2011</year>
<volume>176</volume>
<page-range>328-35</page-range></nlm-citation>
</ref>
<ref id="B25">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Landmark]]></surname>
<given-names><![CDATA[C. J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Targets for antiepileptic drugs in the synapse]]></article-title>
<source><![CDATA[Medical Science Monitor]]></source>
<year>2007</year>
<volume>13</volume>
<page-range>1-7</page-range></nlm-citation>
</ref>
<ref id="B26">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lile]]></surname>
<given-names><![CDATA[J. A.]]></given-names>
</name>
<name>
<surname><![CDATA[Wesley]]></surname>
<given-names><![CDATA[M. J.]]></given-names>
</name>
<name>
<surname><![CDATA[Kelly]]></surname>
<given-names><![CDATA[T. H.]]></given-names>
</name>
<name>
<surname><![CDATA[Hays]]></surname>
<given-names><![CDATA[L. R]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Separate and combined effects of gabapentin and &#916;9- thc in humans discriminating &#916;9-thc]]></article-title>
<source><![CDATA[Behavioural Pharmacology]]></source>
<year>2016</year>
<volume>27</volume>
<page-range>215-24</page-range></nlm-citation>
</ref>
<ref id="B27">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ling]]></surname>
<given-names><![CDATA[W.]]></given-names>
</name>
<name>
<surname><![CDATA[Shoptaw]]></surname>
<given-names><![CDATA[S.]]></given-names>
</name>
<name>
<surname><![CDATA[Hillhouse]]></surname>
<given-names><![CDATA[M.]]></given-names>
</name>
<name>
<surname><![CDATA[Bholat]]></surname>
<given-names><![CDATA[M. A.]]></given-names>
</name>
<name>
<surname><![CDATA[Charuvastra]]></surname>
<given-names><![CDATA[C.]]></given-names>
</name>
<name>
<surname><![CDATA[Heinzerling]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Double-blind placebo-controlled evaluation of the prometa protocol for methamphetamine dependence]]></article-title>
<person-group person-group-type="editor">
<name>
<surname><![CDATA[Doraimani]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
</person-group>
<source><![CDATA[Addiction]]></source>
<year>2012</year>
<volume>107</volume>
<page-range>361-9</page-range></nlm-citation>
</ref>
<ref id="B28">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Mardani-Kivi]]></surname>
<given-names><![CDATA[M.]]></given-names>
</name>
<name>
<surname><![CDATA[Karimi Mobarakeh]]></surname>
<given-names><![CDATA[M.]]></given-names>
</name>
<name>
<surname><![CDATA[Keyhani]]></surname>
<given-names><![CDATA[S.]]></given-names>
</name>
<name>
<surname><![CDATA[Haghighi]]></surname>
<given-names><![CDATA[M.]]></given-names>
</name>
<name>
<surname><![CDATA[Hashemi-Motlagh]]></surname>
<given-names><![CDATA[K.]]></given-names>
</name>
<name>
<surname><![CDATA[Saheb- Ekhtiari]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Arthroscopic bankart surgery: does Gabapentin reduce postoperative pain and opioid consumption? A triple-blinded randomized clinical trial]]></article-title>
<source><![CDATA[Orthop Traumatol Surg Res]]></source>
<year>2016</year>
<volume>102</volume>
<page-range>549-53</page-range></nlm-citation>
</ref>
<ref id="B29">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Marshall]]></surname>
<given-names><![CDATA[K.]]></given-names>
</name>
<name>
<surname><![CDATA[Gowing]]></surname>
<given-names><![CDATA[L.]]></given-names>
</name>
<name>
<surname><![CDATA[Ali]]></surname>
<given-names><![CDATA[R.]]></given-names>
</name>
<name>
<surname><![CDATA[Le Foll]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Pharmacotherapies for cannabis dependence]]></article-title>
<source><![CDATA[Cochrane Database Syst Rev]]></source>
<year>2014</year>
<volume>12</volume>
<page-range>cd008940</page-range></nlm-citation>
</ref>
<ref id="B30">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Martinez-Raga]]></surname>
<given-names><![CDATA[J.]]></given-names>
</name>
<name>
<surname><![CDATA[Sabater]]></surname>
<given-names><![CDATA[A.]]></given-names>
</name>
<name>
<surname><![CDATA[Perez-Galvez]]></surname>
<given-names><![CDATA[B.]]></given-names>
</name>
<name>
<surname><![CDATA[Castellano]]></surname>
<given-names><![CDATA[M.]]></given-names>
</name>
<name>
<surname><![CDATA[Cervera]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Add-on Gabapentin in the treatment of opiate withdrawal]]></article-title>
<source><![CDATA[Prog Neuropsychopharmacol Biol Psychiatry]]></source>
<year>2004</year>
<volume>28</volume>
<page-range>599-601</page-range></nlm-citation>
</ref>
<ref id="B31">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Mason]]></surname>
<given-names><![CDATA[B. J.]]></given-names>
</name>
<name>
<surname><![CDATA[Crean]]></surname>
<given-names><![CDATA[R.]]></given-names>
</name>
<name>
<surname><![CDATA[Goodell]]></surname>
<given-names><![CDATA[V.]]></given-names>
</name>
<name>
<surname><![CDATA[Light]]></surname>
<given-names><![CDATA[J. M.]]></given-names>
</name>
<name>
<surname><![CDATA[Quello]]></surname>
<given-names><![CDATA[S.]]></given-names>
</name>
<name>
<surname><![CDATA[Shadan]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[A proof-ofconcept randomized controlled study of Gabapentin: Effects on cannabis use, withdrawal and executive function deficits in cannabis-dependent adults]]></article-title>
<person-group person-group-type="editor">
<name>
<surname><![CDATA[Rao]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<source><![CDATA[Neuropsychopharmacology]]></source>
<year>2012</year>
<volume>37</volume>
<page-range>1689-98</page-range></nlm-citation>
</ref>
<ref id="B32">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Mellick]]></surname>
<given-names><![CDATA[G. A.]]></given-names>
</name>
<name>
<surname><![CDATA[Mellick]]></surname>
<given-names><![CDATA[L. B]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Management of restless legs syndrome with Gabapentin (Neurontin)]]></article-title>
<source><![CDATA[Sleep]]></source>
<year>1996</year>
<volume>19</volume>
<page-range>224-6</page-range></nlm-citation>
</ref>
<ref id="B33">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Minozzi]]></surname>
<given-names><![CDATA[S.]]></given-names>
</name>
<name>
<surname><![CDATA[Cinquini]]></surname>
<given-names><![CDATA[M.]]></given-names>
</name>
<name>
<surname><![CDATA[Amato]]></surname>
<given-names><![CDATA[L.]]></given-names>
</name>
<name>
<surname><![CDATA[Davoli]]></surname>
<given-names><![CDATA[M.]]></given-names>
</name>
<name>
<surname><![CDATA[Farrell]]></surname>
<given-names><![CDATA[M. F.]]></given-names>
</name>
<name>
<surname><![CDATA[Pani]]></surname>
<given-names><![CDATA[P. P.]]></given-names>
</name>
<name>
<surname><![CDATA[Vecchi]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Anticonvulsants for cocaine dependence]]></article-title>
<source><![CDATA[Cochrane Database Syst Rev]]></source>
<year>1995</year>
<volume>4</volume>
<page-range>cd006754</page-range></nlm-citation>
</ref>
<ref id="B34">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Moghadam]]></surname>
<given-names><![CDATA[M. S.]]></given-names>
</name>
<name>
<surname><![CDATA[Alavinia]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The effects of Gabapentin on methadone based addiction treatment: a randomized controlled trial]]></article-title>
<source><![CDATA[Pak J Pharm Sci]]></source>
<year>2013</year>
<volume>26</volume>
<page-range>985-9</page-range></nlm-citation>
</ref>
<ref id="B35">
<nlm-citation citation-type="book">
<collab>National Center for Biotechnology Information</collab>
<source><![CDATA[Pub Chem Substance Database]]></source>
<year>2018</year>
<publisher-loc><![CDATA[Bethesda, U.S.A: U.S ]]></publisher-loc>
<publisher-name><![CDATA[National Library of Medicine]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B36">
<nlm-citation citation-type="">
<collab>No author listed</collab>
<source><![CDATA[Gabapentin and Pregabalin: abuse and addiction. Prescrire Int, 21]]></source>
<year>2012</year>
<page-range>152-4</page-range></nlm-citation>
</ref>
<ref id="B37">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Olive]]></surname>
<given-names><![CDATA[M. F.]]></given-names>
</name>
<name>
<surname><![CDATA[Cleva]]></surname>
<given-names><![CDATA[R. M.]]></given-names>
</name>
<name>
<surname><![CDATA[Kalivas]]></surname>
<given-names><![CDATA[P. W.]]></given-names>
</name>
<name>
<surname><![CDATA[Malcolm]]></surname>
<given-names><![CDATA[R. J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Glutamatergic medications for the treatment of drug and behavioral addictions]]></article-title>
<source><![CDATA[Pharmacol Biochem Behav]]></source>
<year>2012</year>
<volume>100</volume>
<page-range>801-10</page-range></nlm-citation>
</ref>
<ref id="B38">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Quintero]]></surname>
<given-names><![CDATA[G. C]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Review about Gabapentin misuse, interactions, contraindications and side effects]]></article-title>
<source><![CDATA[J Exp Pharmacol]]></source>
<year>2017</year>
<volume>9</volume>
<page-range>13-21</page-range></nlm-citation>
</ref>
<ref id="B39">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Reimann]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Inhibition by gaba, baclofen and gabapentin of dopamine release from rabbit caudate nucleus: are there common or different sites of action?]]></article-title>
<source><![CDATA[Eur J Pharmacol]]></source>
<year>1983</year>
<volume>94</volume>
<page-range>341-4</page-range></nlm-citation>
</ref>
<ref id="B40">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Rodriguez-Arias]]></surname>
<given-names><![CDATA[M.]]></given-names>
</name>
<name>
<surname><![CDATA[Aguilar]]></surname>
<given-names><![CDATA[M. A.]]></given-names>
</name>
<name>
<surname><![CDATA[Minarro]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Therapies in early development for the treatment of opiate addiction]]></article-title>
<source><![CDATA[Expert Opin Investig Drugs]]></source>
<year>2015</year>
<volume>24</volume>
<page-range>1459-72</page-range></nlm-citation>
</ref>
<ref id="B41">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Rogawski]]></surname>
<given-names><![CDATA[M. A.]]></given-names>
</name>
<name>
<surname><![CDATA[Loscher]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The neurobiology of antiepileptic drugs]]></article-title>
<source><![CDATA[Nat Rev Neurosci]]></source>
<year>2004</year>
<volume>5</volume>
<page-range>553-64</page-range></nlm-citation>
</ref>
<ref id="B42">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Rosner]]></surname>
<given-names><![CDATA[H.]]></given-names>
</name>
<name>
<surname><![CDATA[Rubin]]></surname>
<given-names><![CDATA[L.]]></given-names>
</name>
<name>
<surname><![CDATA[Kestenbaum]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Gabapentin adjunctive therapy in neuropathic pain states]]></article-title>
<source><![CDATA[Clin J Pain]]></source>
<year>1996</year>
<volume>12</volume>
<page-range>56-8</page-range></nlm-citation>
</ref>
<ref id="B43">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Rudolf]]></surname>
<given-names><![CDATA[G.]]></given-names>
</name>
<name>
<surname><![CDATA[Walsh]]></surname>
<given-names><![CDATA[J.]]></given-names>
</name>
<name>
<surname><![CDATA[Plawman]]></surname>
<given-names><![CDATA[A.]]></given-names>
</name>
<name>
<surname><![CDATA[Gianutsos]]></surname>
<given-names><![CDATA[P.]]></given-names>
</name>
<name>
<surname><![CDATA[Alto]]></surname>
<given-names><![CDATA[W.]]></given-names>
</name>
<name>
<surname><![CDATA[Mancl]]></surname>
<given-names><![CDATA[L.]]></given-names>
</name>
<name>
<surname><![CDATA[Rudolf]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[A novel non-opioid protocol for medically supervised opioid withdrawal and transition to antagonist treatment]]></article-title>
<source><![CDATA[Am J Drug Alcohol Abuse]]></source>
<year>2018</year>
<volume>44</volume>
<page-range>302-9</page-range></nlm-citation>
</ref>
<ref id="B44">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ryback]]></surname>
<given-names><![CDATA[R. S.]]></given-names>
</name>
<name>
<surname><![CDATA[Brodsky]]></surname>
<given-names><![CDATA[L.]]></given-names>
</name>
<name>
<surname><![CDATA[Munasifi]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Gabapentin in bipolar disorder]]></article-title>
<source><![CDATA[J Neuropsychiatry Clin Neurosci]]></source>
<year>1997</year>
<volume>9</volume>
<page-range>301</page-range></nlm-citation>
</ref>
<ref id="B45">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ryback]]></surname>
<given-names><![CDATA[R.]]></given-names>
</name>
<name>
<surname><![CDATA[Ryback]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Gabapentin for behavioral dyscontrol]]></article-title>
<source><![CDATA[Am J Psychiatry]]></source>
<year>1995</year>
<volume>152</volume>
<page-range>1399</page-range></nlm-citation>
</ref>
<ref id="B46">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sabioni]]></surname>
<given-names><![CDATA[P.]]></given-names>
</name>
<name>
<surname><![CDATA[Le Foll]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Psychosocial and pharmacological interventions for the treatment of cannabis use disorder]]></article-title>
<source><![CDATA[F1000Res]]></source>
<year>2018</year>
<volume>7</volume>
<page-range>173</page-range></nlm-citation>
</ref>
<ref id="B47">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Salehi]]></surname>
<given-names><![CDATA[M.]]></given-names>
</name>
<name>
<surname><![CDATA[Kheirabadi]]></surname>
<given-names><![CDATA[G. R.]]></given-names>
</name>
<name>
<surname><![CDATA[Maracy]]></surname>
<given-names><![CDATA[M. R.]]></given-names>
</name>
<name>
<surname><![CDATA[Ranjkesh]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Importance of Gabapentin dose in treatment of opioid withdrawal]]></article-title>
<source><![CDATA[J Clin Psychopharmacol]]></source>
<year>2011</year>
<volume>31</volume>
<page-range>593-6</page-range></nlm-citation>
</ref>
<ref id="B48">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sanders]]></surname>
<given-names><![CDATA[N. C.]]></given-names>
</name>
<name>
<surname><![CDATA[Mancino]]></surname>
<given-names><![CDATA[M. J.]]></given-names>
</name>
<name>
<surname><![CDATA[Gentry]]></surname>
<given-names><![CDATA[W. B.]]></given-names>
</name>
<name>
<surname><![CDATA[Guise]]></surname>
<given-names><![CDATA[J. B.]]></given-names>
</name>
<name>
<surname><![CDATA[Bickel]]></surname>
<given-names><![CDATA[W. K.]]></given-names>
</name>
<name>
<surname><![CDATA[Thostenson]]></surname>
<given-names><![CDATA[J.]]></given-names>
</name>
<name>
<surname><![CDATA[Oliveto]]></surname>
<given-names><![CDATA[A. H]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Randomized, placebo-controlled pilot trial of Gabapentin during an outpatient, Buprenorphine-assisted detoxification procedure]]></article-title>
<source><![CDATA[Exp Clin Psychopharmacol]]></source>
<year>2013</year>
<volume>21</volume>
<page-range>294-302</page-range></nlm-citation>
</ref>
<ref id="B49">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Schlicker]]></surname>
<given-names><![CDATA[E.]]></given-names>
</name>
<name>
<surname><![CDATA[Reimann]]></surname>
<given-names><![CDATA[W.]]></given-names>
</name>
<name>
<surname><![CDATA[Gothert]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Gabapentin decreases monoamine release without affecting acetylcholine release in the brain.]]></article-title>
<source><![CDATA[Arzneimittelforschung]]></source>
<year>1985</year>
<volume>35</volume>
<page-range>1347-9</page-range></nlm-citation>
</ref>
<ref id="B50">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Segal]]></surname>
<given-names><![CDATA[A. Z.]]></given-names>
</name>
<name>
<surname><![CDATA[Rordorf]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Gabapentin as a novel treatment for postherpetic neuralgia]]></article-title>
<source><![CDATA[Neurology]]></source>
<year>1996</year>
<volume>46</volume>
<page-range>1175-6</page-range></nlm-citation>
</ref>
<ref id="B51">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Shimoyama]]></surname>
<given-names><![CDATA[M.]]></given-names>
</name>
<name>
<surname><![CDATA[Shimoyama]]></surname>
<given-names><![CDATA[N.]]></given-names>
</name>
<name>
<surname><![CDATA[Inturrisi]]></surname>
<given-names><![CDATA[C. E.]]></given-names>
</name>
<name>
<surname><![CDATA[Elliott]]></surname>
<given-names><![CDATA[K. J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Gabapentin enhances the antinociceptive effects of spinal morphine in the rat tail-flick test]]></article-title>
<source><![CDATA[Pain]]></source>
<year>1997</year>
<volume>72</volume>
<page-range>375-82</page-range></nlm-citation>
</ref>
<ref id="B52">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Singh]]></surname>
<given-names><![CDATA[L.]]></given-names>
</name>
<name>
<surname><![CDATA[Field]]></surname>
<given-names><![CDATA[M. J.]]></given-names>
</name>
<name>
<surname><![CDATA[Ferris]]></surname>
<given-names><![CDATA[P.]]></given-names>
</name>
<name>
<surname><![CDATA[Hunter]]></surname>
<given-names><![CDATA[J. C.]]></given-names>
</name>
<name>
<surname><![CDATA[Oles]]></surname>
<given-names><![CDATA[R. J.]]></given-names>
</name>
<name>
<surname><![CDATA[Williams]]></surname>
<given-names><![CDATA[R. G.]]></given-names>
</name>
<name>
<surname><![CDATA[Woodruff]]></surname>
<given-names><![CDATA[G. N]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The antiepileptic agent Gabapentin (Neurontin) possesses anxiolytic-like and antinociceptive actions that are reversed by D-serine]]></article-title>
<source><![CDATA[Psychopharmacology]]></source>
<year>1996</year>
<volume>127</volume>
<page-range>1-9</page-range><publisher-loc><![CDATA[Berl ]]></publisher-loc>
</nlm-citation>
</ref>
<ref id="B53">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sood]]></surname>
<given-names><![CDATA[A.]]></given-names>
</name>
<name>
<surname><![CDATA[Ebbert]]></surname>
<given-names><![CDATA[J. O.]]></given-names>
</name>
<name>
<surname><![CDATA[Wyatt]]></surname>
<given-names><![CDATA[K. D.]]></given-names>
</name>
<name>
<surname><![CDATA[Croghan]]></surname>
<given-names><![CDATA[I. T.]]></given-names>
</name>
<name>
<surname><![CDATA[Schroeder]]></surname>
<given-names><![CDATA[D. R.]]></given-names>
</name>
<name>
<surname><![CDATA[Sood]]></surname>
<given-names><![CDATA[R.]]></given-names>
</name>
<name>
<surname><![CDATA[Hays]]></surname>
<given-names><![CDATA[J. T]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Gabapentin for smoking cessation]]></article-title>
<source><![CDATA[Nicotine Tob Res]]></source>
<year>2010</year>
<volume>12</volume>
<page-range>300-4</page-range></nlm-citation>
</ref>
<ref id="B54">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Soyka]]></surname>
<given-names><![CDATA[M.]]></given-names>
</name>
<name>
<surname><![CDATA[Mutschler]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Treatment-refractory substance use disorder: Focus on alcohol, opioids, and cocaine]]></article-title>
<source><![CDATA[Prog Neuropsychopharmacol Biol Psychiatry]]></source>
<year>2016</year>
<volume>70</volume>
<page-range>148-61</page-range></nlm-citation>
</ref>
<ref id="B55">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Urschel]]></surname>
<given-names><![CDATA[H. C]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[A controlled trial of Flumazenil and Gabapentin for initial treatment of methylamphetamine dependence]]></article-title>
<person-group person-group-type="editor">
<name>
<surname><![CDATA[Hanselka]]></surname>
<given-names><![CDATA[L. L]]></given-names>
</name>
<name>
<surname><![CDATA[Baron]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<source><![CDATA[J Psychopharmacol]]></source>
<year>2011</year>
<volume>25</volume>
<page-range>254-62</page-range></nlm-citation>
</ref>
<ref id="B56">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Urschel]]></surname>
<given-names><![CDATA[H. C.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Open-label study of a proprietary treatment program targeting type A gamma-aminobutyric acid receptor dysregulation in methamphetamine dependence]]></article-title>
<person-group person-group-type="editor">
<name>
<surname><![CDATA[Hanselka]]></surname>
<given-names><![CDATA[L. L]]></given-names>
</name>
<name>
<surname><![CDATA[Gromov]]></surname>
<given-names><![CDATA[I.]]></given-names>
</name>
<name>
<surname><![CDATA[White]]></surname>
<given-names><![CDATA[L.]]></given-names>
</name>
<name>
<surname><![CDATA[Baron]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<source><![CDATA[Mayo Clin Proc]]></source>
<year>2007</year>
<volume>82</volume>
<page-range>1170-8</page-range></nlm-citation>
</ref>
<ref id="B57">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Vollmer]]></surname>
<given-names><![CDATA[K. O.]]></given-names>
</name>
<name>
<surname><![CDATA[von Hodenberg]]></surname>
<given-names><![CDATA[A.]]></given-names>
</name>
<name>
<surname><![CDATA[Kolle]]></surname>
<given-names><![CDATA[E. U]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Pharmacokinetics and metabolism of Gabapentin in rat, dog and man]]></article-title>
<source><![CDATA[Arzneimittelforschung]]></source>
<year>1986</year>
<volume>36</volume>
<page-range>830-9</page-range></nlm-citation>
</ref>
<ref id="B58">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Walden]]></surname>
<given-names><![CDATA[J.]]></given-names>
</name>
<name>
<surname><![CDATA[Hesslinger]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Value of old and new anticonvulsants in treatment of psychiatric diseases]]></article-title>
<source><![CDATA[Fortschr Neurol Psychiatr]]></source>
<year>1995</year>
<volume>63</volume>
<page-range>320-35</page-range></nlm-citation>
</ref>
<ref id="B59">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Welty]]></surname>
<given-names><![CDATA[D. F.]]></given-names>
</name>
<name>
<surname><![CDATA[Schielke]]></surname>
<given-names><![CDATA[G. P.]]></given-names>
</name>
<name>
<surname><![CDATA[Rothstein]]></surname>
<given-names><![CDATA[J. D]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Potential treatment of amyotrophic lateral sclerosis with Gabapentin: a hypothesis]]></article-title>
<source><![CDATA[Ann Pharmacother]]></source>
<year>1995</year>
<volume>29</volume>
<page-range>1164-7</page-range></nlm-citation>
</ref>
<ref id="B60">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ziaaddini]]></surname>
<given-names><![CDATA[H.]]></given-names>
</name>
<name>
<surname><![CDATA[Ziaaddini]]></surname>
<given-names><![CDATA[A.]]></given-names>
</name>
<name>
<surname><![CDATA[Asghari]]></surname>
<given-names><![CDATA[N.]]></given-names>
</name>
<name>
<surname><![CDATA[Nakhaee]]></surname>
<given-names><![CDATA[N.]]></given-names>
</name>
<name>
<surname><![CDATA[Eslami]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Trial of Tramadol plus Gabapentin for opioid detoxification]]></article-title>
<source><![CDATA[Iran Red Crescent Med J]]></source>
<year>2015</year>
<volume>17</volume>
</nlm-citation>
</ref>
<ref id="B61">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Zullino]]></surname>
<given-names><![CDATA[D. F.]]></given-names>
</name>
<name>
<surname><![CDATA[Khazaal]]></surname>
<given-names><![CDATA[Y.]]></given-names>
</name>
<name>
<surname><![CDATA[Hattenschwiler]]></surname>
<given-names><![CDATA[J.]]></given-names>
</name>
<name>
<surname><![CDATA[Borgeat]]></surname>
<given-names><![CDATA[F.]]></given-names>
</name>
<name>
<surname><![CDATA[Besson]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Anticonvulsant drugs in the treatment of substance withdrawal]]></article-title>
<source><![CDATA[Drugs of Today]]></source>
<year>2004</year>
<volume>40</volume>
<page-range>603-19</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
